Darapladib drug fails to reduce risk of recurrent major coronary events

September 1, 2014 11:47 AM

2 0

Published on September 1, 2014 at 7:46 AM

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent ...

Read more

To category page

Loading...